← All Sponsors

SPONSOR

Novartis Pharmaceuticals

Total Trials

25

Recruiting

25

Phases

Phase 3, Phase 1, Phase 2, Phase 2, Phase 3, Phase 2, Phase 4, Phase 1

Conditions studied: Chronic Myelogenous Leukemia in Chronic Phase Oligometastatic Prostate Cancer (OMPC)Relapsing Multiple Sclerosis Plaque Psoriasis Psoriatic Arthritis Familial Hypercholesterolemia - Heterozygous Asthma Generalized Myasthenia Gravis Atypical Hemolytic Uremic Syndrome Prostate Cancer

RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)

Chronic Myelogenous Leukemia in Chronic Phase

NCT05939414 Phase 3

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Oligometastatic Prostate Cancer (OMPC)

NCT06617793 Phase 1, Phase 2

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

Modifying PEST for Psoriatic Arthritis Screening

Plaque Psoriasis

NCT06597019 Phase 3

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia - Heterozygous

A 24-week rPMS Study in Real-world Setting for Enerzair

NCT06704269 Phase 1, Phase 2

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

NCT05795140 Phase 3

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

Atypical Hemolytic Uremic Syndrome

NCT06780670 Phase 2, Phase 3

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Prostate Cancer

NCT05222529 Phase 2

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

NCT06813911 Phase 3

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Atherosclerotic Cardiovascular Disease (ASCVD)

NCT06991556 Phase 2

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-sensitive Prostate Cancer

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Metastatic Prostate Cancer

NCT05803941 Phase 4

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Prostate Cancer

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

NCT07206056 Phase 1, Phase 2

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Progressive Metastatic Castrate Resistant Prostate Cancer

NCT05677451 Phase 3

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria

NCT06665256 Phase 2

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Idiopathic Inflammatory Myopathies

NCT06824103 Phase 4

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Graft vs. Host Disease

NCT07261631 Phase 1

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Pancreatic Ductal Adenocarcinoma

NCT06655896 Phase 2

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Scleroderma, Diffuse

NCT05126277 Phase 3

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Lupus Nephritis

NCT06514534 Phase 2

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Chronic Myeloid Leukemia (CML)

NCT07039422 Phase 2

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

Primary Immune Thrombocytopenia

A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

Graft-versus-Host Disease